

## Datasheet: TZA025P

<b>Description:</b>	HUMAN ANTI PERTUZUMAB:HRP
<b>Specificity:</b>	PERTUZUMAB
<b>Other names:</b>	Perjeta
<b>Format:</b>	HRP
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD35569
<b>Isotype:</b>	Fab antibody
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

A bivalent human recombinant Fab (kappa light chain) generated by coupling of the monovalent SpyTagged Fab [TZA025](#) with a HRP conjugated BiSpyCatcher version 2 ([TZC002P](#)). The coupled antibody has two DYKDDDDK tags and three His6-tags. It contains SpyTag3 peptide ([BLP086](#)) in 5-fold molar excess to block any unreacted Catcher sites. This antibody is supplied as a liquid.

### Preparation

Metal chelate affinity chromatography

### Source

E.coli

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.0095% MIT

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

**Immunogen**

Pertuzumab

**Specificity**

**Human Anti-Pertuzumab Antibody, clone AbD35569** is a non-paratope specific, non-inhibitory anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug pertuzumab. It recognizes free pertuzumab and pertuzumab in complex with its target, the human epidermal growth factor receptor 2 (HER2) but not free HER2. It can be used to measure total levels of pertuzumab and biosimilars in patient samples.

The monovalent Fab format of this antibody, clone AbD35569ad ([TZA025](#)) is tagged with a SpyTag2 at the C-terminus of the Fab heavy chain, enabling the user to couple it to a [SpyCatcher reagent](#) for conversion to alternative formats in less than one hour.

This antibody is also available as a bivalent Fab antibody pre-coupled to the HRP-conjugated BiSpyCatcher2 ([TZC002P](#)) under product code [TZA025P](#) for direct detection of pertuzumab in bioanalysis assays.

A pair of anti-pertuzumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure total drug. Clone AbD35569 can be used as a detection antibody to develop a pharmacokinetic (PK) bridging assay together with [HCA341](#) as the capture antibody.

Pertuzumab (Perjeta) is an IgG1/kappa antibody humanized from mouse. It has been approved for the treatment of patients with metastatic HER2-positive breast cancer in combination with trastuzumab. Pertuzumab binds to the extracellular domain II of HER2 and inhibits HER2–HER3 dimerization, reducing signaling through intracellular pathways ([Capelan et al. 2013](#)).

[View a summary of all anti-pertuzumab antibodies](#)

**Affinity**

The monovalent intrinsic affinity of AbD35569pap was measured as  $K_D = 31$  nM by real time, label free molecular interaction analysis on immobilized pertuzumab.

**ELISA**

Clone AbD35569pap can be used in direct ELISA to detect pertuzumab. It can also be used as a detection antibody, together with [HCA341](#) as the capture antibody to develop a PK bridging ELISA to detect pertuzumab total drug levels in the serum of patients.

Protocol: [PK bridging ELISA](#)

**Storage**

This product is shipped frozen.

When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for more than one week.

**Guarantee**

12 months from date of despatch

**Acknowledgements**

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See [bio-rad.com/en-us/trademarks](http://bio-rad.com/en-us/trademarks) for details.

His-tag is a registered trademark of EMD Biosciences.  
Perjeta is a trademark of Genentech, Inc.

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20479 available at: <a href="https://www.bio-rad-antibodies.com/SDS/TZA025P">https://www.bio-rad-antibodies.com/SDS/TZA025P</a>
<b>Licensed Use</b>	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols for coupling a Fab antibody with a SpyTag to a SpyCatcher can be found at <a href="#">SpyTag and SpyCatcher Products</a> , and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a>

---

## Related Products

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI PERTUZUMAB \(HCA341\)](#)

[HUMAN ANTI PERTUZUMAB \(HCA342\)](#)

[HUMAN ANTI PERTUZUMAB \(HCA344\)](#)

[HUMAN ANTI PERTUZUMAB \(HCA345\)](#)

[HUMAN ANTI PERTUZUMAB \(TZA025\)](#)

[HUMAN ANTI PERTUZUMAB \(DRUG/TARGET COMPLEX\) \(TZA035\)](#)

[HUMAN ANTI PERTUZUMAB \(DRUG/TARGET COMPLEX\):HRP \(TZA035P\)](#)

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)

'M442424:250528'

**Printed on 20 Jun 2025**